Kim Jung Han, Baek Moo Jun, Ahn Byung-Kwon, Kim Dae Dong, Kim Ik Yong, Kim Jin Soo, Bae Byung-Noe, Seo Bong-Gun, Jung Sang Hun, Hong Kwan Hee, Kim Hungdai, Park Dong Guk, Lee Ji Hye
1. Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University College of Medicine, Seoul 150-950, Korea.
2. Department of Surgery, Soonchunhyang University College of Medicine, Cheonan, Korea.
J Cancer. 2016 Jan 1;7(2):136-43. doi: 10.7150/jca.13405. eCollection 2016.
Adjuvant chemotherapy is a crucial part of treatment for patients with locally advanced colon cancer. This study was conducted to investigate the actual practice in the use of adjuvant chemotherapy for patients with high-risk stage II or stage III colon cancer in South Korea.
This was a 24-month open-label, prospective, observational study conducted at 12 centers across South Korea. Patients with high-risk stage II and stage III colon cancer receiving adjuvant chemotherapy after curative surgery were included, and data were collected at baseline, third, and sixth month.
A total of 246 patients were included in the analyses. Of five available regimens (FOLFOX, CAPOX, 5-FU/LV, capecitabine, and UFT/LV), FOLFOX was most commonly used (82.5%). Investigators indicated the "efficacy" as the major cause for selecting FOLFOX or CAPOX. For 5-FU/LV, capecitabine, or UFT/LV, the "safety" or "patient's characteristics (age, comorbidity, and stage)" was one of the most important selecting factors. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX. Hematologic toxicities were the most common cause of dose adjustment and treatment delay.
In South Korea, FOLFOX was the most commonly used regimen for adjuvant chemotherapy and its efficacy was the main cause for selecting this regimen. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX.
辅助化疗是局部晚期结肠癌患者治疗的关键部分。本研究旨在调查韩国高危II期或III期结肠癌患者辅助化疗的实际应用情况。
这是一项在韩国12个中心进行的为期24个月的开放标签、前瞻性观察性研究。纳入了根治性手术后接受辅助化疗的高危II期和III期结肠癌患者，并在基线、第三个月和第六个月收集数据。
共有246例患者纳入分析。在五种可用方案（FOLFOX、CAPOX、5-FU/LV、卡培他滨和UFT/LV）中，FOLFOX使用最为普遍（82.5%）。研究者指出“疗效”是选择FOLFOX或CAPOX的主要原因。对于5-FU/LV、卡培他滨或UFT/LV，“安全性”或“患者特征（年龄、合并症和分期）”是最重要的选择因素之一。接受5-FU/LV、卡培他滨或UFT/LV治疗的患者比接受FOLFOX或CAPOX治疗的患者年龄更大、PS更差且疾病分期更低（II期）。血液学毒性是剂量调整和治疗延迟的最常见原因。
在韩国，FOLFOX是辅助化疗最常用的方案，其疗效是选择该方案的主要原因。接受5-FU/LV、卡培他滨或UFT/LV治疗的患者比接受FOLFOX或CAPOX治疗的患者年龄更大、PS更差且疾病分期更低（II期）。
